<DOC>
	<DOCNO>NCT01366898</DOCNO>
	<brief_summary>The protocol objective provide adequate treatment base broad consensus elderly patient Acute Lymphoblastic Leukemia ( ALL ) . Apply uniform treatment enables joint analysis result strong enough make conclusion specific subgroup patient ( genotypic subtypes , particularly LAL Bcr/abl positive , phenotype , strata age associate disease ) . Provide result treatment consider standard compare result phase II trial experimental drug undoubtedly activate come year</brief_summary>
	<brief_title>Protocol For Treatment Acute Lymphoblastic Leukemia With Ph 'Negative Elderly Patients ( &gt; 55 Years )</brief_title>
	<detailed_description>Prephase ( day -5 -1 ) Dexamethasone 10 mg/m2 bolus day IV 5 day ( -5 -1 ) . Supplementary treatment : hydration minimum 2000 ml/day , allopurinol 300 mg / day , gastric protection ( center ) , daily monitoring blood glucose , daily monitor renal function . Intrathecal treatment ( diagnosis prophylactic ) day -5 : 12 mg administer intrathecal methotrexate . The morphological study CSF define initial CNS involvement LAL . Although recommended immunophenotypic study CSF , definition CNS involvement LAL ( therapeutic consequence ) base morphological observation blast CSF cytocentrifuge . Remission induction : Tolerance prephase period use establish final indication treatment ( standard protocol frail patient ) . Day 0 free treatment consider +1 first day induction . The total duration induction 30 day , consist two phase ( Phase I , day +1 +14 phase II , day +15 +30 ) . Mandatory test consider counting percentage blast peripheral blood +8 day induction , myelogram day +14 assess early response day +35 ass complete remission ( day +1 +14 ) - Vincristine ( VCR ) 1 mg ( absolute dose ) IV 1 8 . - Idarubicin ( IDA ) : 10 mg ( absolute dose ) IV 1 , 2 , 8 9 . - Dexamethasone ( DEX ) : 10 mg/m2 bolus day 1 2 IV , 8 11 day +15 +30 ) - cyclophosphamide ( CFM ) : 300 mg / 2 iV 1 hour 15 17 . ( 3 total dos ) . - Cytarabine ( ARAC ) : 60 mg / 2 iV 1 hour 16 19 , 23 26 . ( 8 total dos ) . - Vincristine ( VCR ) 1 mg ( absolute dose ) iV 1 8 . - Idarubicin ( IDA ) : 10 mg ( absolute dose ) iV 1 , 2 , 8 9 . - Dexamethasone ( DEX ) : 10 mg/m2 bolus day 1 2 iV , 8 11 Consolidation : Cycles 1 , 3 , 5 MTX : 1,000 mg/m2 , IV infusion 24 hour day 1 L-ASA . 10,000 IU / 2 IV IM Day 2 Cycles 2 , 4 , 6 ARAC : 1,000 mg/m2 , IV 3 hour day 1 , 3 5</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adults 55 year diagnose ALL chromosome Ph 'negative na√Øve 1 . L3 ALL mature B phenotype cytogenetic abnormality ALL characteristic Burkitt type ( [ 8 , 14 ] , [ 2 , 8 ] , [ 8 , 22 ] ) . 2 . Biphenotypic acute leukemia bilinear 3 . Acute undifferentiated leukemia The criteria exclusion treatment ( patient record ) following : 4 . Patients history severe uncontrolled disease , include : Coronary artery disease , valvular hypertensive heart disease . Chronic liver disease ( active viral alcoholic ) . Chronic respiratory failure . Renal failure due ALL . Serious neurological disorder due ALL . f. Improperly control diabetes . 5 . General condition affect ( grade 3 4 WHO scale , see Appendix II ) , attributable LAL . 6 . LAL chromosome Ph 'positive ( must register even follow specific protocol ) . 7 . Lack consent patient use medical record .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>